Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations
AML Hub11 Feb

Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symposium by Gail J. Roboz, Weill Cornell Medicine, New York, US, in which she discussed the management of patients with acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD) and FLT3-tyrosine kinase domain (TKD) mutations in clinical practice.


Roboz reflected on whether 7+3 regimens are the most appropriate approach for older patients with FLT3-mutated AML, and reviewed considerations for using targeted FLT3 inhibitor therapies in combination with standard intensive chemotherapy. She then highlighted the importance of measurable residual disease (MRD) assessment in guiding treatment decisions before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the potential of triplet therapies for the treatment of patients with FLT3m AML.


This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(40)

Menin inhibitors in AML: Where are we now, and where are we going?

Menin inhibitors in AML: Where are we now, and where are we going?

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The di...

22 Mai 30min

Managing side effects of menin inhibitors in clinical practice

Managing side effects of menin inhibitors in clinical practice

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach ...

21 Mai 7min

Mechanisms and rationale for menin inhibitor combination strategies in AML

Mechanisms and rationale for menin inhibitor combination strategies in AML

The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies...

20 Mai 4min

Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy

Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care w...

19 Mai 32min

What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML?

What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML?

The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials...

15 Mai 5min

Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A

Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with...

12 Feb 7min

Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation fro...

19 Jan 20min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-bisarr-historie
foreldreradet
treningspodden
jakt-og-fiskepodden
rss-strid-de-norske-borgerkrigene
mikkels-paskenotter
rss-sunn-okonomi
rss-kunsten-a-leve
sinnsyn
hverdagspsyken
dopet
rss-kull
lederskap-nhhs-podkast-om-ledelse
fryktlos
hagespiren-podcast
gravid-uke-for-uke
hr-podden-2